Cooperative Agreement U01CA289564
- This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
- GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- The University of Pittsburgh received a $180,632 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on halting breast cancer metastasis by blocking cancer-mesenchymal stem cell (MSC) engulfment. The research aims to discover and validate compounds that can inhibit this cancer-MSC engulfment process, as it has been shown to increase cancer cell tumorigenicity, metastatic potential, and resistance to chemotherapy. The 2-year project...
- This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
- This $640,583 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory to conduct research aimed at enhancing the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their anti-tumor immunity and improve treatment outcomes for patients with microsatellite stable metastatic colorectal cancer, who typically respond poorly...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $483,343.83 to the University of New Mexico Health Sciences Center on May 7, 2025, under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on the regulation of ovarian cancer metastasis. The research project, which extends through November 30, 2030, investigates how microenvironmental signals activate the transcription factor C-JUN in ovarian cancer cells and...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 11, 2025, with a completion date of June 30, 2027. This award supports the development of a novel T-cell imaging paradigm utilizing positron emission tomography (PET) agents targeting CD8 and CD4 markers to provide real-time monitoring of endogenous T-cell trafficking, tumor...
- Federal Project Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $416,818 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2025 through July 31, 2027. The award supports preclinical research investigating whether physical activity enhances Chimeric Antigen Receptor (CAR)-T cell immunotherapy effectiveness in metastatic breast cancer by normalizing the tumor microenvironment. The research will employ...
PROMOTION OF METASTASIS BY APOPTOTIC CELLS - PROJECT SUMMARY/ABSTRACT THE GOAL OF MOST CANCER TREATMENTS IS TO INDUCE THE APOPTOTIC DEATH OF TUMOR CELLS; IN MANY CASES THESE TREATMENTS ALSO INDUCE SUBSTANTIAL OFF-TARGET APOPTOSIS IN HEALTHY TISSUES. EVEN IN THE ABSENCE OF THERAPY, THE MAJORITY OF PROSPECTIVE METASTATIC CELLS DIE BY APOPTOSIS, RESULTING IN THE EARLY METASTATIC NICHE BEING RICH IN APOPTOTIC CELL MATERIAL. WHILE NUMEROUS STUDIES HAVE FOCUSED ON THE FEATURES OF TUMOR CELLS THAT ALLOW THEM TO SURVIVE AND METASTASIZE IN THE FACE OF SUCH TREATMENTS, LESS ATTENTION HAS BEEN PAID TO THE INFLUENCE OF DYING CELLS THEMSELVES ON CANCER PROGRESSION. THE WORK PROPOSED HERE WILL INVESTIGATE THE HYPOTHESIS THAT APOPTOTIC CELLS DRIVE EFFICIENT METASTATIC SPREAD OF HEALTHY CANCER CELLS, BECAUSE THEY INITIATE A CASCADE OF PLATELET RECRUITMENT, COAGULATION, AND MYELOID CELL REPROGRAMMING AT METASTATIC SITES. WE WILL ADDRESS THIS HYPOTHESIS BY FOCUSING ON THREE AIMS: FIRST, WE WILL ADDRESS THE ROLE OF PHOSPHATIDYLSERINE EXPOSURE ON APOPTOTIC CELLS IN RECRUITING PLATELETS AND PROMOTING TUMOR CELL SURVIVAL WITHIN THE INTRAVASCULAR NICHE UPON ARRIVAL OF METASTASIZING CELLS TO THE LUNG. SECOND, WE WILL EXAMINE THE INTERFACE BETWEEN APOPTOTIC CELLS, CANCER CELLS, AND THE MYELOID IMMUNE NETWORK OF THE LUNG, DURING EXTRAVASATION AND ESTABLISHMENT OF THE METASTATIC NICHE. THIRD, WE WILL STUDY THE EFFECTS OF APOPTOTIC CELLS ON SPONTANEOUS METASTASIS FROM A PRIMARY TUMOR, AND TEST WHETHER BLOCKING PRO-METASTATIC FEATURES OF APOPTOTIC CELLS CAN REDUCE METASTASIS IN THIS SETTING. WHILE OUR WORK IS FOCUSED ON THE FUNDAMENTAL PROCESSES BY WHICH APOPTOTIC CELLS INFLUENCE METASTASIS, WE SUGGEST THAT IT MAY POINT TOWARD THERAPEUTIC COMBINATIONS THAT PREVENT METASTASIS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/17/26 | ||
| Not listed | $0 | 12/5/25 | ||
| Not listed | $0 | 12/5/25 | ||
| Not listed | $69.9k | 5/22/25 | ||
| Not listed | $69.9k | 5/22/25 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
UWSC15646S | Fred Hutchinson Cancer Center | Cooperative Agreement U01CA289564 | $333.1k | 9/24/25 | |
UWSC15646S | Fred Hutchinson Cancer Center | Cooperative Agreement U01CA289564 | $336.5k | 1/15/25 |